Publications by authors named "P S Strumph"
Background: ANS-6637, an orally bioavailable selective and reversible aldehyde dehydrogenase-2 (ALDH2) inhibitor, is under development for drug and alcohol use disorders. During the elimination of alcohol, ALDH2 metabolizes acetaldehyde to acetate; inhibiting this enzyme can lead to aversive reactions due to the accumulation of acetaldehyde. Thus, understanding the safety and tolerability of ANS-6637 in combination with alcohol is essential.
View Article and Find Full Text PDFArticle Synopsis
- Young adults with type 1 diabetes (T1D) often have higher A1C levels and face greater risks of diabetic ketoacidosis (DKA), prompting a study to explore the use of sotagliflozin, an oral adjunct to insulin, in this population.
- In a 12-week study, participants aged 18-30 with A1C levels of 9.0% or higher were given either sotagliflozin or a placebo alongside insulin; results indicated that sotagliflozin led to greater decreases in A1C levels and improved postprandial glucose and weight compared to the placebo.
- The findings showed that more patients taking sotagliflozin achieved an A1C
Article Synopsis
- The study aimed to assess if adding sotagliflozin to insulin therapy can help adults with type 1 diabetes reach HbA1c goals without gaining weight.
- A analysis of data from two clinical trials involving 1,575 participants showed that those on sotagliflozin had significant reductions in HbA1c levels and weight loss compared to those on placebo.
- The results indicated that a higher percentage of participants on sotagliflozin achieved HbA1c levels below 7% without weight gain, although there was an increased risk of diabetic ketoacidosis compared to the placebo group.
Article Synopsis
- The study investigates the impact of sotagliflozin, a drug that inhibits sodium-glucose cotransporters, on how the body absorbs glucose after eating.
- It involved 24 healthy participants who were given single doses of either sotagliflozin, canagliflozin, or a placebo, and their glucose absorption was measured using a specialized tracer method.
- Results showed that sotagliflozin significantly reduced glucose absorption and insulin levels after meals, suggesting it could effectively manage post-meal blood sugar spikes.
Article Synopsis
- This study evaluated the effects of sotagliflozin, a medication, on adults with type 1 diabetes over 12 weeks in a double-blind trial comparing different doses to a placebo.
- The results showed that sotagliflozin helped reduce glycated hemoglobin (HbA1c), particularly at the 200 mg and 400 mg doses, and led to a reduction in weight and increased glucose excretion.
- Overall, the medication improved glycemic control without significantly increasing the risk of severe low blood sugar or diabetic ketoacidosis, indicating it could be a beneficial addition to insulin therapy for type 1 diabetes patients.